NSE: TORNTPHARM | BSE: 500420

Expensive Performer

Download real time

3433.50 -6.10 (-0.18%)

Near 52W High of ₹3590.70

293.5K NSE+BSE Volume

NSE 16 Jul, 2025 12:55 PM (IST)

116,205.2

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Torrent Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for TORNTPHARM, BSE:500420 Torrent Pharmaceuticals Ltd.

Torrent Pharmaceuticals Ltd.

02 Jul 2020

3433.50

-0.18%

Torrent Pharmaceuticals Ltd

Sell: Torrent Pharmaceuticals Ltd.

Karvy

Valuation and Risks: We downgrade our Revenues by 4.4% / 4.8% for FY21E / FY22E due to downgrade across regions.

Torrent Pharmaceutic.. has an average target of 3720.40 from 6 brokers.

Torrent Pharmaceuticals Ltd.

27 May 2020

3433.50

-0.18%

Torrent Pharmaceuticals

Hold: Torrent Pharmaceuticals Ltd.

Target

ICICI Securities Limited

India growth steady; acquisitions to enhance coverage Domestic branded formulations including CRAMs constitute 50% of sales. The acquisition of Elder Pharma's branded portfolio has added new therapies like neutraceuticals, gynaecology and helped fill up portfolio gaps. The Unichem acquisition has added branded portfolio comprising some power brands besides achievement of long term synergy benefits. We...

Torrent Pharmaceutic.. has an average target of 3720.40 from 6 brokers.

Torrent Pharmaceuticals Ltd.

27 May 2020

3433.50

-0.18%

Torrent Pharmaceuticals Ltd

Sell: Torrent Pharmaceuticals Ltd.

Recommendation Target

Karvy

Tepid Revenues, Near Term Outlook Uncertain: Revenues for the quarter increased by 5% to Rs19.5 bn due to tepid performance in Europe, Brazil and US.

Torrent Pharmaceutic.. has an average target of 3720.40 from 6 brokers.

Torrent Pharmaceuticals Ltd.

26 May 2020

3433.50

-0.18%

Torrent Pharma

Sell: Torrent Pharmaceuticals Ltd.

Dolat Capital

While India continue to lead growth (pre-buying in March aided growth, in-line), exports were a drag. Gross margin at 72.4% was a function of strong growth in India, leading to impressive EBITDA margin of 28.2% (our estimate: 25.4%). Though company remains confident of outperforming IPM growth, we remain wary of the exports (US 2 key facilities under WL and OAI, Brazil adverse currency and batch traceability regulations in Germany) given the weaker outlook....

Torrent Pharmaceuticals Ltd. is trading above all available SMAs

Torrent Pharmaceuticals Ltd.

20 Apr 2020

3433.50

-0.18%

Torrent Pharmaceuticals

Hold: Torrent Pharmaceuticals Ltd.

Target

ICICI Securities Limited

On the business front, despite the nationwide lockdown, domestic growth is expected to remain more or less stable. Exports growth, barring for one or two months due to congestion in all major ports globally, is also expected to remain strong due to 1) currency benefit, 2) slowdown in competition due to delay in new approvals that will be beneficial for existing players and 3) expected demand continuum across the world despite Covid-19. Some windfall is also expected in some critical productsa case in point is Hydroxychloroquine, a malaria drug that is likely to be repurposed as a prophylaxis for Covid-19 treatment in some cases....

Torrent Pharmaceutic.. has an average target of 3720.40 from 6 brokers.

Torrent Pharmaceuticals Ltd.

17 Feb 2020

3433.50

-0.18%

Torrent Pharmaceuticals Ltd: Pharmaceuticals

Buy: Torrent Pharmaceuticals Ltd.

Recommendation Target

Karvy

Visible Growth in Revenues and MarginsTorrent Pharma s woes in various markets appears to be receding and is all set to show double digit topline growth in key markets which will give impetus to increase in margins.

Torrent Pharmaceuticals Ltd. is trading above all available SMAs

Torrent Pharmaceuticals Ltd.

03 Feb 2020

3433.50

-0.18%

TORRENT PHARMA

Hold: Torrent Pharmaceuticals Ltd.

Target

Geojit BNP Paribas

Torrent Pharmaceuticals Limited (TRP) engages in the research, development, manufacturing and marketing of generic pharmaceutical formulations in India, the US, Germany, Brazil and internationally. The...

Torrent Pharmaceutic.. has an average target of 3720.40 from 6 brokers.

Torrent Pharmaceuticals Ltd.

28 Jan 2020

3433.50

-0.18%

Torrent Pharma (Update): India business holds the Key. BUY

Buy: Torrent Pharmaceuticals Ltd.

Recommendation Target

HDFC Securities

Downside risks: delay in resolution of Dahej (OAI) and Indrad (WL), slower growth in India and launch delays in the US. We resume coverage on Torrent Pharma (TRP) with a Buy. Torrent has re-rated substantially in the past three years on the back of strong execution particularly in branded markets. Despite rich valuation, we recommend Buy as TRP offers a solid India franchise, robust earnings growth and superior return profile which justifies the premium over peers. TRP would generate Rs56bn of FCF over FY19-22E. Our TP of Rs 2,250 is based on 15x FY22 EV/EBIDTA implying a target PE of 28x.

Torrent Pharmaceuticals Ltd. is trading above all available SMAs

Torrent Pharmaceuticals Ltd.

28 Jan 2020

3433.50

-0.18%

Torrent Pharmaceuticals

Hold: Torrent Pharmaceuticals Ltd.

Recommendation

ICICI Securities Limited

India growth steady; acquisitions to enhance coverage Domestic branded formulations including CRAMs constitute 48% of sales. The acquisition of Elder Pharma's branded portfolio has added new therapies like neutraceuticals, gynaecology and helped fill up portfolio gaps. The Unichem acquisition has added branded portfolio comprising some power brands besides achievement of long term synergy benefits. We...

ICICI Securities Limited increased Hold price target of Torrent Pharmaceuticals Ltd. to 3500.0 on 01 Jul, 2025.

Torrent Pharmaceuticals Ltd.

27 Jan 2020

3433.50

-0.18%

India/RoW steady; low interest cost supports earnings

Neutral: Torrent Pharmaceuticals Ltd.

Target

Motilal Oswal

27 January 2020 Torrent Pharma (TRP) has exhibited a robust 23% CAGR (FY14-19) in domestic formulation (DF) sales, executing well both organically and inorganically. However, this benefit is getting offset to some extent by the ongoing regulatory issues at its Dahej/Indrad sites for the US generics business. We maintain our EPS estimate for FY20/21/22 to factor in better operating leverage in DF and increased market share in US generics. Maintain Neutral given the limited upside from current levels. India business (INR8.7b) grew by a moderate 4.3% (partly due to a high base of past year). Adjusting for one-offs due to the integration of TRP and Unichems stockists, India business growth stands at 8.5% YoY. Brazil business was up 12.5% YoY at INR1.9b. US business was down 22% YoY to INR3.

Torrent Pharmaceuticals Ltd. is trading above all available SMAs

Is Torrent Pharmaceuticals Ltd. worth buying?

149 Votes:

Buy 75.17%

Sell 16.11%

Hold 8.72%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf